CMMBNasdaq

Chemomab Therapeutics Ltd.

Healthcare·Immunology·Phase 2·Tel Aviv-Yafo, Israel
Immunology

Chemomab Therapeutics Ltd. (CMMB): 1 pipeline candidate · 1 clinical trial. Updated within the last hour.

6.7/10

BioSniper Score

4-factor signal · derived from public data

Cash RunwayN/A

N/A

Financial Health9.6

D/E 0.12

Pipeline Maturity6.0

Lead: Phase 2

Pipeline Breadth3.3

1 candidate

Catalyst MomentumN/A

N/A

Insider Signal8.0

2 buys · 0 sells (180d)

A transparent, data-derived signal for Chemomab Therapeutics Ltd.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$11.8M

Cash

$7.6M

Quarterly Burn

Runway

Revenue

Pipeline (1 candidate)

DrugPhase
10 mg/kg cm-101Phase 2

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

13

Total value held

$458K

HolderSharesValue
adar1 capital management, llc80,000$126K
citadel advisors llc64,182$101K
kestra private wealth services, llc61,710$97K
xtx topco ltd18,629$29K
rhumbline advisers18,366$29K
smartharvest portfolios, llc14,566$23K
susquehanna international group, llp13,491$21K
bnp paribas financial markets8,425$13K
gamma investing llc7,579$12K
morgan stanley4,575$7K

Showing top 10 of 13 institutional holders of Chemomab Therapeutics Ltd.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

1 clinical trial·CEO: Dr. Adi Mor George Ph.D.

Frequently asked questions

How many drug candidates are in Chemomab Therapeutics Ltd.'s pipeline?

Chemomab Therapeutics Ltd. (CMMB) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.

What is Chemomab Therapeutics Ltd.'s lead drug candidate?

Chemomab Therapeutics Ltd.'s most advanced tracked candidate is 10 mg/kg cm-101 (Phase 2) for Systemic Sclerosis.

What is Chemomab Therapeutics Ltd.'s market capitalization?

Chemomab Therapeutics Ltd.'s market capitalization is approximately $11.8M.

Who is the CEO of Chemomab Therapeutics Ltd.?

Dr. Adi Mor George Ph.D. is the chief executive officer of Chemomab Therapeutics Ltd. (CMMB).

Get the full picture on Chemomab Therapeutics Ltd.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.